GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.
CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech
Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears
Bayer has agreed terms for its first biopharma takeover in years, paying $300m upfront for Perfuse and its novel drug implant for eye diseases.
Shares in Novo Nordisk rose this morning after its highly anticipated first-quarter results revealed better-than-expected uptake of oral Wegovy.
A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo.
Novo’s pill had sales of 2.3 billion Danish …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844